{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:45:44Z","timestamp":1791963944135,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euf.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:55:42Z","timestamp":1791960942000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine\/Docetaxel in BCG-unresponsive Non\u2013muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study"],"prefix":"10.1016","author":[{"given":"Yu Guang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dudinec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.H.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ghoreifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.P.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Abern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.09.008_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2026.09.008_b0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0015","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"Nepple","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0030","article-title":"Evaluating BCG response in primary and metachronous non-muscle invasive bladder cancer following prior upper tract urothelial cancer: a systematic review and meta-analysis","volume":"8","author":"Tan","year":"2026","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0035","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euf.2026.09.008_b0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/01.JU.0001111604.90306.91.02","article-title":"Final results: Bond-003 cohort C- phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk bcg-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ","volume":"213","author":"Tyson","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0065","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO-25-01651","article-title":"TAR-200 for Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0070","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","article-title":"Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Gu\u00e9rin in patients with Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer","volume":"8","author":"Taylor","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0080","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bju.16645","article-title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","volume":"135","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.09.008_b0085","doi-asserted-by":"crossref","first-page":"520.e1","DOI":"10.1016\/j.urolonc.2025.03.024","article-title":"Intravesical gemcitabine and docetaxel in patients with recurrent high-grade nonmuscle invasive bladder cancer-a prospective cohort study","volume":"43","author":"Pijpers","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0090","doi-asserted-by":"crossref","first-page":"40.e17","DOI":"10.1016\/j.urolonc.2019.07.022","article-title":"An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0095","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.urolonc.2022.10.030","article-title":"Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer","volume":"41","author":"Chevuru","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0100","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.urolonc.2014.02.020","article-title":"BCG refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study","volume":"33","author":"Herr","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bju.16733","article-title":"Radical cystectomy mortality in older patients: a systematic review and meta-analysis","volume":"136","author":"Tempo","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.09.008_b0110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euros.2022.12.016","article-title":"Patient preferences for treatment of Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: a cross-country choice experiment","volume":"49","author":"Collacott","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2026.09.008_b0115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.euf.2021.07.018","article-title":"Sequential gemcitabine plus docetaxel is the standard second-line intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer: pro","volume":"8","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.09.008_b0120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/MOU.0000000000001342","article-title":"Bacillus Calmette-Gu\u00e9rin unresponsive NMIBC: novel therapies and concepts","volume":"35","author":"Gontero","year":"2025","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bju.16087","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?","volume":"132","author":"Tan","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.09.008_b0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bju.16675","article-title":"Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer","volume":"136","author":"Scilipoti","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2026.09.008_b0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eururo.2025.02.010","article-title":"A systematic review of novel intravesical approaches for the treatment of patients with non-muscle-invasive bladder cancer","volume":"88","author":"Ghodoussipour","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO-25-01324","article-title":"Twelve-month results from the CISTO study comparing radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle-invasive bladder cancer","volume":"44","author":"Gore","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2025.09.4137","article-title":"Cost-effectiveness analysis of treatments for Bacillus Calmette-Gu\u00e9rin-unresponsive carcinoma in situ of the bladder","volume":"89","author":"Myers","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0160","doi-asserted-by":"crossref","first-page":"e1338","DOI":"10.1097\/01.JU.0001110188.58981.bc.05","article-title":"PD37-05 Oncologic outcomes in patients undergoing radical cystectomy for NMIBC following BCG therapy failure","volume":"213","author":"Oberneder","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2026.09.008_b0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.euo.2020.06.010","article-title":"Best practices to optimise quality and outcomes of transurethral resection of bladder tumours","volume":"4","author":"Mostafid","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.09.008_b0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/UA.UA_138_19","article-title":"Role of surgeon experience in the outcome of transurethral resection of bladder tumors","volume":"12","author":"Ali","year":"2020","journal-title":"Urol Ann"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692600221X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692600221X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:55:46Z","timestamp":1791960946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692600221X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"alternative-id":["S240545692600221X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.09.008","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Oncological and Patient-reported Outcomes of Intravesical Gemcitabine\/Docetaxel in BCG-unresponsive Non\u2013muscle-invasive Bladder Cancer: A Multi-institutional Prospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}